Join me and world-renowned #GIcancer experts on October 13-14 for the 20th Annual Meeting of the International Society of Gastrointestinal Oncology® (ISGIO)! Register here and use my last name as a code to receive FREE registration
bit.ly/3KpjM54

Один еврей выжил в Заксенхаузене. Каждый день он видел, как зондеркоманды жгут трупы его соотечественников в печах на «станции Z». И вот однажды он прочитал, как слон на Бали растоптал какого-то немца и грустно усмехнулся. Но все вокруг сказали ему – ты расчеловеченная скотина.

Будем объективны!
В отравлении Навального стороны обвинили друг друга. ФБК выдвинул версию о отравителях из ФСБ, провластные структуры обвинили Марию Певчих.
Я, как независимый эксперт, считают, что организм Навального был изношен, что и привело к ухудшению его здоровья.

Is the paper you need stuck behind a paywall? Here is a list of useful websites to help you access the research you need.

* unpaywall.org
* paperpanda.app
* 12ft.io
* openaccessbutton.org
* ilovephd.com/working-sci-hu…

A11-2
Here's a list of a few recent great review articles on immunotherapy for MSS CRC.
📌pubmed.ncbi.nlm.nih.gov/31447840/
📌pubmed.ncbi.nlm.nih.gov/34110510/
📌pubmed.ncbi.nlm.nih.gov/37207140/
📌pubmed.ncbi.nlm.nih.gov/36816981/
📌pubmed.ncbi.nlm.nih.gov/35658496/
📌pubmed.ncbi.nlm.nih.gov/34369996/

#CRCTrialsChat OncoAlert #CRCSM

The Japanese Clinical Practice Guidelines for intrahepatic cholangiocarcinoma: a comparison with Western guidelines hbsn.amegroups.com/article/view/1…

#PDAC - Pancreatic head

6 SMA 1st approaches described and commonly used

Sharing the proposed 7th - 'Retromesenteric Approach'. Useful for uninate tomours abuttung SMA from posterior aspect. 1/2

Amir M Parray IHPBA IHPBA India TeamSurgery SoMe4HPB E-AHPBA

Video👇

Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. ja.ma/41pnSkk #AACR23

Incredible ORR 62% in GDC-6036 combo w/ cetuximab for KRAS G12C mut colorectal cancer which represents ~3% of the US patient popn. #AACR23

Looking forward to drug development targeting KRAS G12D/V that represents ~22% of patients w/ colorectal cancer!

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy - ESMO Open esmoopen.com/article/S2059-…

Very nice table of V600E and atypical #BRAF mutations in CRC

Was surprised to see the name of Lillys new experimental Alzheimer’s antibody — remternetug — didn’t end in “mab,” as all antibody drugs do

Learned that, apparently, the 3-decade era of “mab” ended last year, as scientists just ran out of new names(???)

ncbi.nlm.nih.gov/pmc/articles/P…

A5-1b
Drug development takes a long time...
📌For #KRAS , a rocky process over ~40 years
📌Challenging at every step, many failed attempts including clinical trials
📌Until recently, most attempts indirect, targeting pathway but not #KRAS itself
#CRCTrialsChat

Further reading:
What's on your list?
1. nature.com/articles/s4146…
2. insight.jci.org/articles/view/…
3. sciencedirect.com/science/articl…
4. annualreviews.org/doi/abs/10.114…
5. nature.com/articles/s4141…
6. acsjournals.onlinelibrary.wiley.com/doi/full/10.10…
7. ncbi.nlm.nih.gov/pmc/articles/P…
8. nature.com/articles/s4157…
#CRCTrialsChat #CRCSM

🔥A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic #ColorectalCancer in 🇺🇸
Journal of the @NCCN
doi.org/0.6004/jnccn.2…
🔎1,937 pts
👉no difference -> mOS 6.66 vs 6.30 mo
😇Will TAS-102 leapfrog in SUNLIGHT?
ESMO - Eur. Oncology OncoAlert

@MyESMO Molecular selection & monitoring of adjuvant strategies for patients with CRC: tissue, liquid, and combos
Intro Dr. Julien Taieb
A research glimpse in the ctDNA-driven future of managing localized colon cancer, talk by Dr Jeanne Tie #CRCSM

MyESMO Molecular selection & monitoring of adjuvant strategies for patients with CRC: tissue, liquid, and combos
Intro Dr. Julien Taieb
A research glimpse in the ctDNA-driven future of managing localized colon cancer, talk by Dr Jeanne Tie #CRCSM

MyESMO Molecular selection & monitoring of adjuvant strategies for patients with CRC: tissue, liquid, and combos
Intro Dr. Julien Taieb
A research glimpse in the ctDNA-driven future of managing localized colon cancer, talk by Dr Jeanne Tie #CRCSM
Trials for stage II & III

patients with CRC: tissue, liquid, and combos
Intro Dr. Julien Taieb
Research insights from neoadjuvant approaches across molecular subgroups of localized CRC, talk by Dr Jenny Seligmann
#CRCSM